<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">OXACILLIN SODIUM</span><br/>(ox-a-sill'in)<br/><span class="topboxtradename">Bactocill, </span><span class="topboxtradename">Prostaphlin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic penicillin</span>; <span class="classification">antistaphylococcal penicillin</span><br/><b>Prototype: </b>Penicillin G<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg, 500 mg capsules; 250 mg/5 mL suspension; 250 mg, 500 mg, 1 g, 2 g injection</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic, acid-stable, penicillinase-resistant isoxazolyl penicillin.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>In common with other isoxazolyl penicillins (cloxacillin, dicloxacillin), it is highly active against most penicillinase-producing
         staphylococci, is less potent than penicillin G against penicillin-sensitive microorganisms, and is generally ineffective
         against gram-negative bacteria and methicillin-resistant staphylococci (MRSA).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Primarily, infections caused by penicillinase-producing staphylococci and penicillin-resistant staphylococci. May be used
         to initiate therapy in suspected staphylococcal infections pending culture and sensitivity test results. As with other penicillins,
         serum concentrations are enhanced by concurrent use of probenecid.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to penicillins or cephalosporins. Safe use during pregnancy (category B) is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of or suspected atopy or allergy (hives, eczema, hay fever, asthma); premature infants, neonates, lactation (may cause
         infant diarrhea).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">
<i>Staphylococcal</i> Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2501000 mg q46h <span class="rdroute">IM/IV</span> 500 mg2 g q46h up to 12 g/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 50100 mg/kg/d in 4 divided doses <span class="rdroute">IM/IV</span> 50150 mg/kg/d divided q46h<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV</span> 50100 mg/kg/d divided q612h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p>
         			Note: The total sodium content (including that contributed by buffer) in each gram of oxacillin is approximately 3.1 mEq or 71 mg.
         		
      </p><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with a full glass of water on an empty stomach (either 1 h before meals or 2 h after meals). Food reduces absorption.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute each 250 mg with 1.4 mL sterile water for injection to yield 250 mg/1.5 mL. Shake vial vigorously until drug
            is completely dissolved. Discard unused portions after 3 d at room temperature or 7 d under refrigeration.
         </li>
<li>Administer deep IM to adults by deep intragluteal injection. Follow agency policy for IM site in young children and infants.
            Rotate injection sites.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravascular</span><p>
                  				Note: Verify correct IV concentration and rate of infusion/injection with physician before IV administration to neonates, infants,
                  children.
                  			
               </p>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute each 500 mg or fraction thereof with 5 mL with sterile water for injection or NS to yield 250 mg/1.5 mL.  <span class="methodtype">Intermittent:</span> Further dilute in 50100 mL of D5W, NS, D5/NS, or RL.  <span class="methodtype">Continuous:</span> Further dilute in up to 1000 mL of compatible IV solutions.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give at a rate of 1 g or fraction thereof over 10 min.  <span class="methodtype">Intermittent:</span> Give over 1530 min.  <span class="methodtype">Continuous:</span> Give over 6 h.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution:</span> <span class="incompattype">additive:</span> Cytarabine <span class="incompattype"> Y-site:</span>
<b>Sodium bicarbonate,</b>
<b>verapamil.</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Thrombophlebitis (IV therapy), superinfections, wheezing, sneezing, fever, <span class="speceff-life">anaphylaxis</span>. <span class="typehead">GI:</span> Nausea, vomiting, flatulence, <span class="speceff-common">diarrhea,</span> hepatocellular dysfunction (elevated AST, ALT, hepatitis). <span class="typehead">Hematologic:</span> Eosinophilia, leukopenia, thrombocytopenia, granulocytopenia, <span class="speceff-life">agranulocytosis</span>; neutropenia (reported in children). <span class="typehead">Skin:</span> Pruritus, rash, urticaria. <span class="typehead">Urogenital:</span> Interstitial nephritis, transient hematuria, albuminuria, azotemia (newborns and infants on high doses). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Oxacillin in large doses can cause false-positive <span class="alt">urine protein tests</span> using sulfosalicylic acid methods.
      </p>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Incompletely and erratically absorbed orally. <span class="typehead">Peak:</span> 30120 min IM; 15 min IV. <span class="typehead">Duration:</span> 4 h PO; 46 h IM. <span class="typehead">Distribution:</span> Distributes into CNS with inflamed meninges; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Enters enterohepatic circulation. <span class="typehead">Elimination:</span> Primarily excreted in urine, some in bile. <span class="typehead">Half-Life:</span> 0.51 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Ask patient prior to first dose about hypersensitivity reactions to penicillins, cephalosporins, and other allergens.</li>
<li>Lab tests: periodic liver functions, CBC with differential, platelet count, and urinalysis.</li>
<li>Hepatic dysfunction (possibly a hypersensitivity reaction) has been associated with IV oxacillin; it is reversible with discontinuation
            of drug. Symptoms may resemble viral hepatitis or general signs of hypersensitivity and should be reported promptly: hives,
            rash, fever, nausea, vomiting, abdominal discomfort, anorexia, malaise, jaundice (with dark yellow to brown urine, light-colored
            or clay-colored stools, pruritus).
         </li>
<li>Withhold next drug dose and report the onset of hypersensitivity reactions and superinfections (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take oral medication around the clock, do not miss a dose. Take all of the medication prescribed even if you feel better,
            unless otherwise directed by physician.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>